Global /China /Healthcare /Biotechnology /300759
chevron_leftBack

Pharmaron Beijing Co., Ltd.

300759
SHE: 300759 Delayed
22.72CNY 2.3%
3.12 USD
As of 24 April 2025, Pharmaron Beijing Co., Ltd. has a market cap of $5.1B USD, ranking #2802 globally and #431 in China. It ranks #246 in the Healthcare sector, and #51 in the Biotechnology industry.
Global Rank
2802
Country Rank
431
Sector Rank
246
Industry Rank
51
Key Stats
Market Cap
$5.1BUSD
37.19B CNY
Enterprise Value
$5.59BUSD
40.7B CNY
Revenue (TTM)
$1.68BUSD
12.28B CNY
EBITDA (TTM)
$354.4MUSD
2.58B CNY
Net Income (TTM)
$246.1MUSD
1.79B CNY
EBITDA Margin
21%
Profit Margin
15%
PE Ratio
22.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Boliang Lou open_in_new
Employees
21,370
Founded
2004
Website
pharmaron.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
2.3% 1.1% -17% -9.8% -21% 25%

Markets

Exchange Ticker Price
Shenzhen Stock Exchange
MIC: XSHE
PRIMARY
300759
康龙化成(北京)新药技术股份有限公司 Class A
ISIN: CNE100003JW4
Shares Out.:
1.475B1 Shares Float: 826.683M2
TV:
SA:
YF:
GF:
BA:
MS:
22.72 CNY
Hong Kong Stock Exchange
MIC: XHKG
3759
康龙化成(北京)新药技术股份有限公司 Ordinary Shares - Class H
ISIN: CNE100003PG4
Shares Out.:
301.537M1 Shares Float: 301.537M2
TV:
SA:
YF:
GF:
BA:
MS:
13.72 HKD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Co., Ltd., together with its subsidiaries, provides drug research and development, and production services to the life sciences industry in North America, Europe, Japan, Mainland China, and internationally. The company offers laboratory chemistry services, including medicinal and synthetic chemistry, chemistry for new modalities, radiolabelling and radiosynthesis, analytical and purification chemistry, DNA-encoded libraries, cheminformatics, and computer-aided drug design; bioscience services, such as structural biology, in vitro biology, DMPK, in vivo pharmacology, and compound management services; chemistry, manufacturing, and controls services. It also provides clinical development services, including integrated radio labelled science, clinical development, and clinical trial recruitment services; safety assessment, integrated drug discovery, and bioanalysis services; and biologics and cell and gene therapy services, comprising biologics laboratory, biologics CDMO, cell and gene therapy laboratory, and gene therapy CDMO services. Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.

Similar Companies

Industry: Biotechnology (China)
Name
Market Cap diff.
WuXi Biologics (Cayman) Inc.
2269
$11.84B
91.89B HKD
132%
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392
$11.38B
82.93B CNY
123%
Innovent Biologics, Inc.
1801
$10.93B
84.8B HKD
114%
Akeso, Inc.
9926
$10.75B
83.38B HKD
111%
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
6990
$9.03B
70.04B HKD
77%
Industry: Biotechnology (Global)
Name
Market Cap diff.
Vertex Pharmaceuticals Inc.
VRTX
$126.59B
2K%
CSL Ltd.
CSL
$74.13B
116.09B AUD
1K%
Regeneron Pharmaceuticals, Inc.
REGN
$62.91B
1K%
Samsung Biologics Co.,Ltd.
207940
$52.85B
75.87T KRW
936%
argenx SE
ARGX
$36.51B
32.22B EUR
615%